Q2 EPS Estimate for Elanco Animal Health Lowered by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for Elanco Animal Health in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $0.20 per share for the quarter, down from their prior forecast of $0.26. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's FY2027 earnings at $1.07 EPS and FY2028 earnings at $1.24 EPS.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the firm posted $0.34 earnings per share. Elanco Animal Health's revenue for the quarter was down 1.0% compared to the same quarter last year.

Several other research firms have also recently weighed in on ELAN. Barclays cut their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus raised their price objective on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Finally, Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Elanco Animal Health has an average rating of "Hold" and an average target price of $15.00.

Elanco Animal Health Trading Up 7.2%

NYSE:ELAN traded up $0.86 during trading hours on Friday, hitting $12.82. The stock had a trading volume of 7,583,788 shares, compared to its average volume of 4,997,314. Elanco Animal Health has a one year low of $8.02 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $6.36 billion, a price-to-earnings ratio of 32.04, a P/E/G ratio of 2.50 and a beta of 1.49. The business's 50 day moving average is $9.93 and its 200-day moving average is $11.42.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $10.90 per share, with a total value of $109,000.00. Following the completion of the transaction, the director now owns 101,459 shares in the company, valued at approximately $1,105,903.10. This trade represents a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ELAN. FMR LLC grew its position in Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. Nuveen LLC bought a new position in Elanco Animal Health in the first quarter valued at $115,212,000. Norges Bank bought a new position in Elanco Animal Health in the fourth quarter valued at $47,424,000. Brandes Investment Partners LP grew its position in shares of Elanco Animal Health by 66.9% in the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock valued at $69,405,000 after acquiring an additional 2,296,691 shares during the period. Finally, ASR Vermogensbeheer N.V. bought a new position in shares of Elanco Animal Health in the 1st quarter valued at about $23,744,000. Institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.